Skip to main content
Premium Trial:

Request an Annual Quote

Dominion Diagnostics Licenses Rights to LifeGen Genetic Test Technology

NEW YORK (GenomeWeb News) – Dominion Diagnostics today said that it has licensed rights to genetic testing technology from LifeGen.

The firms are currently collaborating on a study to validate LifeGen's test, which determines a patient's Genetic Addiction Risk Score. The test is being compared in the study to the Addiction Severity Index marketed by Inflexxion.

The LifeGen test includes a panel of genes primarily involved in brain reward circuitry, said North Kingston, RI-based Dominion Diagnostics. The firms, however, didn't provide specific details of which genes are in the panel, but they noted that a subset of the population "carries the DRD2 Type A1 receptor gene, which induces low dopamine brain function that results in the propensity for addictive cravings."

Further details of the alliance and licensing agreement were not disclosed.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.